banner
 
bar

program

slides
bar
 
 

Real World, Case-Based Approaches to Optimizing Management of Gastrointestinal Neuroendocrine Tumors (NETs)

WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.5 hours

Course Overview

In this web-based program, physicians will learn how recent developments in multimodal therapies have advanced the management of gastrointestinal neuroendocrine tumors (NETs).

Release Date

July 11, 2017

Expiration Date

July 11, 2019

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 11, 2017 through July 11, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 7 segments totaling 2.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals. 

Grantor Support

Supported by an educational grant from Ipsen

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. University of Massachusetts Medical School  is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

EDWARD M. WOLIN, MD – Program Chair
Professor of Medicine
Albert Einstein College of Medicine
Director of the Neuroendocrine Tumor Program
Montefiore Einstein Center for Cancer Care
New York, NY

Consultant: Ipsen, Novartis, Celgene
 

JAMES C. YAO, MD
Professor and Chairman
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consultant: Novartis, Ipsen, Merck


ALEXANDRIA T. PHAN, MD
Professor
University of New Mexico Comprehensive Cancer Center

Consultant: Ipsen, Lexicon
Speaker’s Bureau: Ipsen, Novartis, Genentech, Lilly



SCOTT PAULSON, MD
Assistant Professor
Texas A & M
Gastrointestinal Oncologist
Texas Oncology – Baylor Charles A. Sammons Cancer Center
Dallas, Texas

Nothing to disclose


Educational Objectives

Upon completion of this activity, participants will be able to:

  • Detail the epidemiology, burden, and clinical challenges associated with detecting, diagnosing and classifying gastroenteropancreatic neuroendocrine tumors (GEP- NETs);
  • Classify GEP- NETs, into WHO- generated categories of: (a) well- differentiated NETs; and (2) poorly- differentiated neuroendocrine carcinomas (NECs) of the small- or large- cell type; and explain how further classification into functional and non- functional, and origin of the tumor, can impact management and treatment choices;
  • Apply clinical practice guidelines for GEP- NETs from the European Society for Medical Oncology (ESMO), from NCCN, and other expert consensus panels, and therefore, become more clinically proficient at utilizing these evidence- based guidelines to the from lines of GI oncology practice;
  • Determine which patients with metastatic GEP- NET are appropriate for the use of surgical interventions (resection), medical therapy, systemic chemotherapy, and peptide receptor- targeted radiotherapy, based on presentation, symptoms, tumor types and stage, clinical profiles, extent of disease, biomarkers, and other factors;
  • Deploy emerging pharmacologic treatments for patients with GEP- NETs, including somatostatin analogs (SSAs), radiolabeled SSAs, cytotoxic drugs, angiogenesis inhibitors, and mammalian target of rapamycin (mTOR) inhibitors in patients with metastatic GEP- NETs.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2017 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

AKT
carcinoid
Chemotherapy
c-KIT
CLARINET
colon cancer
EGFR
ELECT
Everolimus
GEP-NET
GI malignancy 

IGF-1R
Lanreotide
Lanreotide Autogel
metastatic
mTOR
NANETs/NCCN
NET
NETTER-1
Octreotide LAR
pancreatic adenocarcinoma

 

pancreatic neuroendocrine tumors
Pasireotide
PDGF
peptide receptor radiotherapy
phosphoinositide-3-kinase
pNET
PROMID
CLARINET

GEPNETs
PRRT 
RADIANT-3
Octreotide
REMINET
Somatostatin Analog
stomach adenocarcinoma
streptozocin
Sunitinib
SYMNET
Tumors